Zalifrelimab
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4) . Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling[1].
Product Specifications
CAS Number
2148321-69-9
Product Name Alternative
AGEN1884
UNSPSC
12352203
Target
CTLA-4
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zalifrelimab.html
Purity
98.28
Solubility
10 mM in DMSO
Smiles
[Zalifrelimab]
Molecular Weight
(144.48 kDa)
References & Citations
[1]David M O'Malley, et al. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2022 Mar 1;40 (7) :762-771. |[2]Randi B Gombos, et al. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PLoS One. 2018 Apr 4;13 (4) :e0191926.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
ELI-12534b 96 Tests
Bovine Inhibitor of growth protein 4, ING4 ELISA KIT
Sign In for Pricing
View Details 
ARP37976_P050-FITC 100 µL
CIITA Antibody - middle region : FITC (ARP37976_P050-FITC)
Sign In for Pricing
View Details 